Secondary Hodgkin Lymphoma and MDS after Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer

The rapid development of new therapies that improve patients ’ quality of life and treat various diseases has led to occurrence of more complex adverse drug reactions. This is obvious in cancer therapy where adverse events are more often neglected by the clinicians because of the primary goal of cancer therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marija Petrushevska, Irina Panovska Stavrdis, Gordana Petrusevska Source Type: research